Related Experiment Videos
Angiotensin-I-converting enzyme and its relatives.
1Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School, One Kendall Square, Cambridge, MA 02139, USA. james_riordan@hms.harvard.edu
Genome Biology
|August 14, 2003
Summary
Angiotensin-I-converting enzyme (ACE) regulates blood pressure and is crucial for treating hypertension. New structure insights into ACE active sites may enable improved drug design for fewer side effects.
Area of Science:
- Biochemistry
- Enzymology
- Pharmacology
Background:
- Angiotensin-I-converting enzyme (ACE) is a key enzyme in the renin-angiotensin system, regulating blood pressure.
- ACE inhibitors are vital for hypertension treatment.
- Two human ACE forms exist: somatic (ubiquitous) and germinal (sperm-specific), derived from the same gene via alternative promoters.
Purpose of the Study:
- To elucidate the structural basis of ACE function and inhibition.
- To explore the potential for structure-based drug design of novel ACE inhibitors.
Main Methods:
- X-ray crystallography of truncated germinal ACE and a Drosophila homolog.
- Analysis of active site structure and location within a central cavity.
Main Results:
- The active site of ACE is located deep within a central cavity.
- Somatic ACE possesses two distinct active sites, while germinal ACE has one.
- ACE homologs are found across diverse species.
Conclusions:
- Structural data provides a foundation for rational drug design targeting ACE.
- Structure-based approaches may yield next-generation ACE inhibitors with improved safety profiles.
- Understanding ACE structure is critical for advancing cardiovascular and hypertension therapies.